Experienced in Shwachman-Diamond Syndrome

Dr. Joseph W. Rosenthal

Pediatric Hematology Oncology
1500 E Duarte Rd, 
Duarte, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Shwachman-Diamond Syndrome
1500 E Duarte Rd, 
Duarte, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Joseph Rosenthal is a Pediatric Hematologist Oncology provider in Duarte, California. Dr. Rosenthal is rated as an Experienced provider by MediFind in the treatment of Shwachman-Diamond Syndrome. His top areas of expertise are Sickle Cell Disease, Leukemia, Hemoglobinopathy, Graft Versus Host Disease (GvHD), and Bone Marrow Transplant.

His clinical research consists of co-authoring 46 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Shwachman-Diamond Syndrome.

Specialties
Pediatric Hematology Oncology
Licenses
Pediatrics in CA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID

Locations

1500 E Duarte Rd, Duarte, CA 91010

Additional Areas of Focus

Dr. Rosenthal has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Pilot Study of Nonmyeloablative Regimen Using Total Marrow and Lymphoid Irradiation for Irradiation Sparing of Bystander Organs in Hematopoietic Cell Transplantation From Matched Related or Unrelated Donor in Patients With Sickle Cell Disease
A Pilot Study of Nonmyeloablative Regimen Using Total Marrow and Lymphoid Irradiation for Irradiation Sparing of Bystander Organs in Hematopoietic Cell Transplantation From Matched Related or Unrelated Donor in Patients With Sickle Cell Disease
Enrollment Status: Recruiting
Publish Date: December 31, 2024
Intervention Type: Radiation, Procedure, Drug
Study Phase: Phase 1
A Pilot Study To Evaluate The Safety And Feasibility of Hematopoietic Progenitor Cell Mobilization With Plerixafor as Part of a Gene Therapy Strategy in Sickle Cell Disease
A Pilot Study To Evaluate The Safety And Feasibility of Hematopoietic Progenitor Cell Mobilization With Plerixafor as Part of a Gene Therapy Strategy in Sickle Cell Disease
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Drug
Study Drug: Plerixafor
Study Phase: Phase 1
Phase I Study of Escalating Doses of Total Marrow and Lymphoid Irradiation (TMLI) During Conditioning for HLA-Haploidentical Hematopoietic Cell Transplantation With Post-Transplant Cyclophosphamide in Patients With Myelodysplasia or Acute Leukemia
Phase I Study of Escalating Doses of Total Marrow and Lymphoid Irradiation (TMLI) During Conditioning for HLA-Haploidentical Hematopoietic Cell Transplantation With Post-Transplant Cyclophosphamide in Patients With Myelodysplasia or Acute Leukemia
Enrollment Status: Completed
Publish Date: June 22, 2025
Intervention Type: Drug, Procedure, Other, Radiation
Study Drugs: Cyclophosphamide, Fludarabine Phosphate, Mycophenolate Mofetil, Tacrolimus
Study Phase: Phase 1
Pilot Study to Evaluate the Safety and Feasibility of Induction of Mixed Chimerism in Sickle Cell Disease Patients With COH-MC-17: a Non-Myeloablative, Conditioning Regimen and CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant
Pilot Study to Evaluate the Safety and Feasibility of Induction of Mixed Chimerism in Sickle Cell Disease Patients With COH-MC-17: a Non-Myeloablative, Conditioning Regimen and CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant
Enrollment Status: Active_not_recruiting
Publish Date: April 23, 2025
Intervention Type: Biological, Drug
Study Drugs: Cyclophosphamide, Pentostatin, Rabbit anti-thymocyte globulin, Tacrolimus, Mycophenolate mofetil, CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant
Study Phase: Phase 1
Allogeneic Stem Cell Transplantation for Patients With Hematological Malignancies Using Multiple Unrelated Cord Blood Units
Allogeneic Stem Cell Transplantation for Patients With Hematological Malignancies Using Multiple Unrelated Cord Blood Units
Enrollment Status: Completed
Publish Date: June 14, 2024
Intervention Type: Biological, Drug, Procedure, Radiation
Study Drugs: Filgrastim, Busulfan, Cyclophosphamide, Cyclosporine, Fludarabine, Melphalan, Mycophenolate Mofetil
Study Phase: Not Applicable
A Phase 1 Pilot Study to Evaluate the Safety and Feasibility of Gene Therapy With CSL200 (Autologous Enriched CD34+ Cell Fraction That Contains CD34+ Cells Transduced With Lentiviral Vector Encoding Human γ-GlobinG16D and Short-Hairpin RNA734) in Adult Subjects With Severe Sickle Cell Disease
A Phase 1 Pilot Study to Evaluate the Safety and Feasibility of Gene Therapy With CSL200 (Autologous Enriched CD34+ Cell Fraction That Contains CD34+ Cells Transduced With Lentiviral Vector Encoding Human γ-GlobinG16D and Short-Hairpin RNA734) in Adult Subjects With Severe Sickle Cell Disease
Enrollment Status: Terminated
Publish Date: June 18, 2021
Intervention Type: Biological
Study Phase: Phase 1
View 5 Less Clinical Trials

46 Total Publications

Phase 1 dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies.
Phase 1 dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies.
Journal: Cancer medicine
Published: February 29, 2024
Similar Doctors
Advanced in Shwachman-Diamond Syndrome
Dr. Loan Hsieh
Pediatric Hematology Oncology
Advanced in Shwachman-Diamond Syndrome
Dr. Loan Hsieh
Pediatric Hematology Oncology
1010 W La Veta Ave, 
Orange, CA 
 (24.9 miles away)
714-221-1200
Languages Spoken:
English
See accepted insurances

Loan Hsieh is a Pediatric Hematologist Oncology provider in Orange, California. Dr. Hsieh is rated as an Advanced provider by MediFind in the treatment of Shwachman-Diamond Syndrome. Her top areas of expertise are Hereditary Spherocytosis, Thalassemia, Hemolytic Anemia, Shwachman-Diamond Syndrome, and Splenectomy.

Advanced in Shwachman-Diamond Syndrome
Dr. Maritza E. Ruiz
Pediatric Hematology Oncology
Advanced in Shwachman-Diamond Syndrome
Dr. Maritza E. Ruiz
Pediatric Hematology Oncology
1201 West La Veta Avenue, 
Orange, CA 
 (24.8 miles away)
714-509-8636
Languages Spoken:
English
See accepted insurances

Maritza Ruiz is a Pediatric Hematologist Oncology provider in Orange, California. Dr. Ruiz is rated as an Advanced provider by MediFind in the treatment of Shwachman-Diamond Syndrome. Her top areas of expertise are Hereditary Spherocytosis, Immune Thrombocytopenic Purpura (ITP), Febrile Neutropenia, and Evans Syndrome.

Advanced in Shwachman-Diamond Syndrome
Dr. David K. Buchbinder
Pediatric Hematology Oncology
Advanced in Shwachman-Diamond Syndrome
Dr. David K. Buchbinder
Pediatric Hematology Oncology

Childrens Hospital Of Orange County

1201 W La Veta Ave, 
Orange, CA 
 (24.8 miles away)
888-770-2462
Languages Spoken:
English
See accepted insurances

David Buchbinder is a Pediatric Hematologist Oncology provider in Orange, California. Dr. Buchbinder is rated as a Distinguished provider by MediFind in the treatment of Shwachman-Diamond Syndrome. His top areas of expertise are Wiskott-Aldrich Syndrome, Severe Combined Immunodeficiency (SCID), X-Linked Severe Combined Immunodeficiency, Aplastic Anemia, and Bone Marrow Transplant.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rosenthal's expertise for a condition
ConditionClose
      View All 10 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile